Medicare Part D coverage · cholestyramine resin · RxCUI 848949
cholestyramine resin 4000 MG Powder for Oral Suspension [Questran]
Per the CMS 2026 Part D formulary file, cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] is covered by 6 Medicare Part D plans (0.1% of enrollable products), averaging Tier 2, with prior authorization required on 0% of covering formularies.
- 0.1%
- Plan coverage
- 6
- Plans covering
- T2
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for cholestyramine resin 4000 MG Powder for Oral Suspension [Questran]
Per the CMS 2026 Part D formulary file, cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] (RxNorm concept RXCUI 848949, generic name cholestyramine resin) appears on 1 distinct formulary file spanning 6 Medicare Part D plan offerings - 0.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 2 to Tier 2, with a cross-plan average of Tier 2.
Real-world access to cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 186,287 Part D beneficiaries filled cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] in 2023, with total plan-and-beneficiary spending of $47,685,796 and an average per-beneficiary annual cost of $255.98. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] today.
Coverage Details
- Formularies covering
- 1
- Plans covering
- 6
- Coverage rate
- 0.1%
- Tier range
- Tier 2, Generic
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 186,287
- Total spending
- $47,685,796
- Avg per beneficiary
- $255.98
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering cholestyramine resin 4000 MG Powder for Oral Suspension [Questran]
6 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| Keystone 65 Select Rx (HMO) | Keystone Health Plan East, Inc. | T2 | No | $47.00 | PA |
| Keystone 65 Preferred Rx (HMO) | Keystone Health Plan East, Inc. | T2 | No | $59.70 | PA |
| Keystone 65 Select Rx (HMO) | Keystone Health Plan East, Inc. | T2 | No | $63.50 | PA |
| Keystone 65 Preferred Rx (HMO) | Keystone Health Plan East, Inc. | T2 | No | $79.70 | PA |
| Personal Choice 65 Rx (PPO) | QCC Insurance Company | T2 | No | $102.20 | PA |
| Personal Choice 65 Rx (PPO) | QCC Insurance Company | T2 | No | $112.70 | PA |
Frequently Asked Questions
Is cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] covered by Medicare Part D?
Yes, cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] is covered by 6 Medicare Part D plans (0.1% of all Part D formularies).
What tier is cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] on Medicare Part D plans?
cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] averages Tier 2 across Part D plans, ranging from Tier 2 to Tier 2.
Does cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] require prior authorization?
0% of Part D formularies require prior authorization for cholestyramine resin 4000 MG Powder for Oral Suspension [Questran]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on cholestyramine resin 4000 MG Powder for Oral Suspension [Questran]?
In 2023, total Medicare Part D spending on cholestyramine resin 4000 MG Powder for Oral Suspension [Questran] was $47,685,796, covering 186,287 beneficiaries. The average spend per beneficiary was $255.98.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA